OS Therapies announced $10 million in debt financing supported by UK VAT refunds and R&D tax credits, providing financial stability into 2027. The company is preparing for key FDA and MHRA meetings in September 2026 to review survival data and finalize Phase 3 trial designs for OST-HER2, a gene-edited cancer immunotherapy targeting metastatic osteosarcoma. Regulatory submissions for accelerated approval are planned in the US, UK, and Europe by the end of 2026. The company also reported a net operating loss of $8.576 million for Q2 2026, driven by R&D and regulatory expenses, while progressing towards potential early market access and Priority Review Voucher eligibility.
Zentek Ltd. has filed a provisional patent for ZEN-EMI-01, a water-based electromagnetic interference (EMI) shielding coating made from purified graphite from its Albany deposit. Unlike traditional metal-based shields that reflect EM energy, this coa...
A new 2026 tax rule phases out a bonus deduction for taxpayers aged 65 and older based on modified adjusted gross income (MAGI). Retirees doing Roth IRA conversions to fill tax brackets may unintentionally lose this valuable deduction if their MAGI e...
Solana (SOL) is trading near $75, maintaining support above the crucial $60-$62 zone after a significant decline from its $253 peak. The recent Alpenglow upgrade, which drastically reduces transaction finality times, has been approved by over 98% of ...
A couple sold a long-held property in 2024, generating a large capital gain that raised their reported income for 2024. This higher income triggered increased Medicare premiums for 2026, as Medicare uses tax data from two years prior to set premiums....
Nebius (NBIS) has been upgraded to a Buy rating due to positive technical signals and strong momentum in the AI sector. The company benefits from over $40 billion in customer commitments, asset-light partnerships, and growing recurring revenue stream...
